Overview
Masashi Kondo practices in Toyoake, Japan. Mr. Kondo is rated as an Advanced expert by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Cancer, Lymphofollicular Hyperplasia, Non-Small Cell Lung Cancer (NSCLC), Endoscopy, and Shoulder Arthroscopy.
His clinical research consists of co-authoring 101 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lymphofollicular Hyperplasia.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Lung CancerMr. Kondo isDistinguished. Learn about Lung Cancer.
- Advanced
- CraniotabesMr. Kondo isAdvanced. Learn about Craniotabes.
- EGFR Positive Lung CancerMr. Kondo isAdvanced. Learn about EGFR Positive Lung Cancer.
- Lymphofollicular HyperplasiaMr. Kondo isAdvanced. Learn about Lymphofollicular Hyperplasia.
- Non-Small Cell Lung Cancer (NSCLC)
- Experienced
- Acute Interstitial PneumoniaMr. Kondo isExperienced. Learn about Acute Interstitial Pneumonia.
- Acute Respiratory Distress Syndrome (ARDS)
- CataractMr. Kondo isExperienced. Learn about Cataract.
- Cerebral HypoxiaMr. Kondo isExperienced. Learn about Cerebral Hypoxia.
- Congenital Fiber-Type DisproportionMr. Kondo isExperienced. Learn about Congenital Fiber-Type Disproportion.
- COVID-19Mr. Kondo isExperienced. Learn about COVID-19.